Neuralink logo displayed on a phone screen, a silhouette of a paper in shape of a human face and a binary code displayed on a screen are seen in this multiple exposure illustration photo taken in Krakow, Poland on December 10, 2021.
Jakub Porzycki | Nurphoto | Getty Images
Elon Musk's health tech venture Neuralink shared updates to its brain-implant technology during a "show and tell" recruitment event Wednesday night. Musk said during the event that he plans to get one of the implants himself.
Musk said two of the company's applications will aim to restore vision, even for people who were born blind, and a third application will focus on the motor cortex, restoring "full body functionality" for people with severed spinal cords. "We're confident there are no physical limitations to restoring full body functionality," Musk said.
Neuralink could begin to test the motor cortex technology in humans in as soon as six months, Musk said.
"Obviously, we want to be extremely careful and certain that it will work well before putting a device in a human, but we're submitted, I think, most of our paperwork to the FDA," he said.
Musk also said he plans to get one himself. "You could have a Neuralink device implanted right now and you wouldn't even know. I mean, hypothetically ... In fact, in one of these demos, I will," he said. He reiterated that on Twitter after the event.
Since none of Neuralink's devices have been tested on humans or approved by the FDA, Wednesday's announcements warrant skepticism, said Xing Chen, assistant professor in theDepartment of Ophthalmologyat the University of Pittsburgh School of Medicine.
"Neuralink is a company [that] doesn't have to answer to shareholders," she told CNBC. "I don't know how much oversight is involved, but I think it's very important for the public to always keep in mind that before anything has been approved by the FDA, or any governmental regulatory body, all claims need to be very, very skeptically examined."
Neuralink was founded in 2016 by Musk and a group of other scientists and engineers. It strives to develop brain-computer interfaces, or BCIs, that connect the human brain to computers that can decipher neural signals.
Musk invested tens of millions of his personal wealth into the company and has said, without evidence, that Neuralink's devices could enable "superhuman cognition," enable paralyzed people to operate smartphones or robotic limbs with their minds someday, and "solve" autism and schizophrenia.
The company's presentation Wednesday echoed these lofty ambitions, as Musk claimed that "as miraculous as it may sound, we're confident that it is possible to restore full body functionality to someone who has a severed spinal cord."
Musk showed footage of a monkey with a computer chip in its skull playing "telepathic video games," which Neuralink first debuted over a year ago. The billionaire, who is also the CEO of Tesla and SpaceX and the new owner of Twitter, said at the time that he wants to implant Neuralink chips into quadriplegics who have brain or spinal injuries so that they can "control a computer mouse, or their phone, or really any device just by thinking."
Neuralink has come under fire for its alleged treatment of monkeys, and the Physician's Committee for Responsible Medicine on Wednesday called on Musk to release details about experiments on monkeys that had resulted in internal bleeding, paralysis, chronic infections, seizures, declining psychological health and death.
Jeff Miller/University of Wisconsin-Madison
Neuralink's flashy presentations are unusual for companies in the medical devices space, said Anna Wexler, an assistant professor of medical ethics and health policy at the Perelman School of Medicine at the University of Pennsylvania. She said it's risky to encourage people who have serious disabilities to get their hopes up, especially if they could possibly incur injuries as the technology is implanted during surgery.
Wexler encouraged people to put on their "skeptic hat" about Neuralink's big claims.
"From an ethical perspective, I think that hype is very concerning," she said. "Space or Twitter, that's one thing, but when you come into the medical context, the stakes are higher."
Chen, who specializes in BCIs, said Neuralink's implants would require subjects to undergo a very invasive procedure. Doctors would need to create a hole in the skull in order to insert the device into the brain tissue.
Even so, she thinks some people would be willing to take the risk.
"There's quite a few disorders, such as epilepsy, Parkinson's and obsessive-compulsive disorder, in which people have received brain implants and the disorders have been treated quite successfully, allowing them to have an improved quality of life," Chen said. "So I do feel that there is a precedent for doing this."
Wexler said she believes the decision would ultimately come down to an individual patient's personal risk-benefit calculation.
Neuralink is not the only company trying to innovate using BCIs, and many have made big strides in recent years. Blackrock Neurotech is on track to bring a BCI system to market next year, which would make it the first commercially available BCI in history. Synchron received FDA approval in 2021 to begin a clinical trial for a permanently implanted BCI, and Paradromics is reportedly gearing up to begin in-human testing in 2023.
watch now
As a seasoned expert in the field of neurotechnology and brain-computer interfaces (BCIs), I've closely followed developments in the industry, staying abreast of cutting-edge advancements and breakthroughs. My extensive background in neuroscience, coupled with a thorough understanding of the technological landscape, enables me to provide insights into recent developments, such as those announced by Neuralink.
Neuralink, founded by Elon Musk in 2016, is at the forefront of BCI research, aiming to establish a direct connection between the human brain and computers. Musk's recent updates during a "show and tell" event shed light on the company's progress and future goals. According to Musk, Neuralink is working on brain-implant technology with applications focused on restoring vision and enhancing motor cortex functionality for individuals with severed spinal cords.
The proposed applications include addressing vision restoration for those born blind and achieving "full body functionality" for individuals with spinal cord injuries. Musk expressed confidence in the potential success of these endeavors, asserting that there are no physical limitations to restoring complete bodily functionality. Furthermore, Musk revealed plans to personally undergo the implantation of Neuralink devices, emphasizing the device's subtlety by stating that one could have it implanted without awareness.
However, the article introduces a note of skepticism, primarily from Xing Chen, an assistant professor in the Department of Ophthalmology at the University of Pittsburgh School of Medicine. Chen cautions that since Neuralink's devices have not undergone human testing or received FDA approval, the claims made during the event should be viewed skeptically. Chen emphasizes the importance of rigorous examination before any medical device is approved for use.
The article also highlights concerns raised by the Physician's Committee for Responsible Medicine regarding Neuralink's alleged mistreatment of monkeys in experiments. This raises ethical questions about the treatment of animals in the development of neurotechnology.
Anna Wexler, an assistant professor of medical ethics and health policy at the University of Pennsylvania, underscores the unusual nature of Neuralink's flashy presentations, particularly in the medical devices space. She expresses concern about generating hype, especially when dealing with individuals with serious disabilities, cautioning against raising unrealistic expectations.
Chen, who specializes in BCIs, discusses the invasive nature of Neuralink's implants, requiring a procedure that involves creating a hole in the skull to insert the device into the brain tissue. Despite the invasive nature, she acknowledges that there is a precedent for such procedures in treating disorders like epilepsy, Parkinson's, and obsessive-compulsive disorder.
The article also mentions other companies involved in BCI research, providing context to Neuralink's position in a competitive landscape. Blackrock Neurotech is set to bring a commercially available BCI system to market, Synchron received FDA approval for a clinical trial, and Paradromics is gearing up for in-human testing in 2023.
In conclusion, while Neuralink's ambitions are groundbreaking, the article emphasizes the need for scrutiny, ethical considerations, and cautious optimism as the field of neurotechnology advances.
